| Literature DB >> 35975173 |
Melanie Brinkmann1, Isabell von Holt1, Leonie Diedrich1, Christian Krauth1, Gabriele Seidel1, Maren Dreier1.
Abstract
Purpose: This qualitative study is part of the SIGMO study, which evaluates general populations' preferences for colorectal cancer (CRC) screening in Germany using a discrete choice experiment. Attribute identification and selection are essential in the construction of choice tasks and should be evidence-based ensuring that attributes are relevant to potential beneficiaries and contribute to overall utility. Therefore, this qualitative study aims to identify relevant attributes characterizing CRC screening tests from the perspective of those eligible for screening in Germany. Patients andEntities:
Keywords: attribute identification; colorectal cancer screening; discrete choice experiment; focus groups; qualitative study
Year: 2022 PMID: 35975173 PMCID: PMC9375991 DOI: 10.2147/PPA.S365429
Source DB: PubMed Journal: Patient Prefer Adherence ISSN: 1177-889X Impact factor: 2.314
A Priori Identified Attributes Characterizing Colorectal Cancer Screening Tests by Categories
| Categories | Attributes |
|---|---|
| Procedure-related characteristics | Procedure |
| Frequency | |
| Preparation | |
| Location | |
| Follow-up test required | |
| Duration | |
| Mode of test delivery | |
| Purpose | |
| Test characteristics | Sensitivity |
| Specificity | |
| 1-Specificity | |
| 1-Sensitivity | |
| Proportion of false positives in relation to all screenees | |
| Benefits | Reduction in colorectal cancer mortality (and incidence) |
| Colorectal cancer survival | |
| Harms | Test-related pain and/or discomfort |
| Risk of complications | |
| Structural characteristics of health care | Out-of-pocket costs |
| Information processes | |
| Travel time to screening facility | |
| Waiting time for follow-up test | |
| Supervision | |
| Level of evidence | Level of evidence |
Self-Reported Characteristics of Focus Group Participants (n=20)
| Characteristics | Total (n, %) | Focus Groups (n, %) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n=20 | FG 1, n=6 | FG 2, n=5 | FG 3, n=5 | FG 4, n=4 | ||||||
| Sex, female | 10 | 50.0 | 3 | 50.0 | 3 | 60.0 | 0 | 0.0 | 4 | 100.0 |
| Age, years (mean, SD) | 55.8±2.2 | 55.3±3.7 | 53.0±3.4 | 57.0±3.2 | 58.0±1.6 | |||||
| General education level, CASMIN | ||||||||||
| Low | 3 | 15.0 | 1 | 16.7 | 1 | 20.0 | 0 | 0.0 | 1 | 25.0 |
| Mediate | 3 | 15.0 | 0 | 0.0 | 1 | 20.0 | 1 | 20.0 | 1 | 25.0 |
| High | 14 | 70.0 | 5 | 83.3 | 3 | 60.0 | 4 | 80.0 | 2 | 50.0 |
| Prior colorectal cancer screening experience | ||||||||||
| FOBT, yes | 10 | 50.0 | 3 | 50.0 | 2 | 40.0 | 3 | 60.0 | 2 | 50.0 |
| Colonoscopy, yes | 10 | 50.0 | 6 | 100.0 | 0 | 0.0 | 2 | 40.0 | 2 | 50.0 |
| Last colonoscopy | ||||||||||
| Never | 10 | 50.0 | 0 | 0.0 | 5 | 100.0 | 3 | 60.0 | 2 | 50.0 |
| Within the past 12 months | 4 | 20.0 | 2 | 33.3 | 0 | 0.0 | 1 | 20.0 | 1 | 25.0 |
| 1 to less than 5 years ago | 4 | 20.0 | 3 | 50.0 | 0 | 0.0 | 1 | 20.0 | 0 | 0.0 |
| 5 to less than 10 years ago | 2 | 10.0 | 1 | 16.7 | 0 | 0.0 | 0 | 0.0 | 1 | 25.0 |
Abbreviations: CASMIN, Comparative Analysis of Social Mobility in Industrial Nations; FG, focus group; FOBT, fecal occult blood test; SD, standard deviation.
Introductory, Transition, and Key Questions Used in the Focus Groups, Based on Morgan and Krueger 199826
| Introduction | What is the first thing that comes to your mind about bowel cancer screening? |
| Transition | Which bowel cancer screening tests do you know, and what do you think are the differences between them? |
| What is your personal experience with bowel cancer screening tests, or what have you heard from relatives or friends? | |
| What were or would be reasons for you personally to decide for or against taking part in a certain bowel cancer screening test? | |
| Providing background information about stool-based testing and colonoscopy | |
| Key | What is particularly important for you in a bowel cancer screening test? |
| In the literature, [attribute] has been identified as relevant for decision-making in bowel cancer screening. How important do you think this is when deciding for or against a bowel cancer screening test? |
Note: All questions provided in this table have been translated from German into English for publication purposes only.
Deductively Assigned (n=19; n=217 Codes) and Inductively Derived (n=5; n=76 Codes) Attributes Related to Colorectal Cancer Screening Tests, Their Relevance for Decision-Making, and Anchor Samples Across All Four Focus Groups
| Category | Codes, n (%) | Attribute | Codes, n | Anchor Sample |
|---|---|---|---|---|
| Procedure-related characteristics | 161 (55) | Preparation | 39 | “But was there anyone, I understood the discussion differently, who would really say, because of the increased time involved in bowel cleansing, I’ll forgo the colonoscopy and do the stool test instead? So, I didn’t understand anyone that way.” (FG 1, P5) |
| “Actually, I have never met anyone who said you can drink it. In fact, I only know people who say it tastes terrible. No matter what you dilute it with. […] Some have thrown up from it, too. That’s also when I think (sighs), ‘Do I need this?’ […] These are all things that have so far made me—that I just have not done that yet.” (FG 2, P) | ||||
| “So, I just found the purging bad, because that’s annoying.” (FG 3, P4) | ||||
| Procedure | 37 | “In my opinion, you can’t compare them. One is an examination to see if I have blood in my stool. And the other is definitely looking at the bowel.” (FG 3, P3) | ||
| Sedationa | 22 | “[…] I also suffer from an anxiety disorder. You have to be anesthetized. These are all things that have so far made me—that I just haven’t done that yet.” (FG 2, P) | ||
| “[…] You get such a nice drug that you don’t care about anything. If I hadn’t known why I was here today, I would have said I had a glass of champagne, I’m fine and wonderful and every time again.” (FG 4, P) | ||||
| Purpose | 14 | “Yes, I think that’s totally important. That is one of the central points. […] If we have a colonoscopy, we can do that right away. This way, we can exclude this very decisive point, the further progression in the case of minor abnormalities. I think that‘s a very strong argument for this procedure. Instant treatment.” (FG 2, P4) | ||
| Inability to worka | 11 | “I think the difference is, of course, the expenditure of time. If I do a colonoscopy, I must have a really great employer, if you have just started somewhere new: ‘Hey, I need a vacation, I need time off.’ […] It’s time-consuming, at least in my opinion. You accept that. You want to know what’s going on, I’d say. But it certainly plays a big role for one or the other, I think.” (FG 4, P2) | ||
| “[…] but what is associated with a colonoscopy in terms of recovery, I think ‘Yes, that’s acceptable’ […] If the result buys you a period of long free time. What use is it to me if the whole thing is not time-consuming, the whole procedure, and I sit there again in half a year and can think ‘What now?’”. (FG 3, P2) | ||||
| “Well, I solved it this way: I had put the appointment on a Monday. And so I had Friday, half day, Saturday, Sunday and that’s quite enough time for the preparation. And then Monday you can do the thing.” (FG 3, P5) | ||||
| Frequency | 11 | “For me, it was not a criterion at all.” (FG 1, P2) | ||
| “But with regard to colonoscopy, I have to say that this minimum interval of ten years really confuses me. If it was five years, I would have more confidence. I don’t know. So, it’s just an emotional thing.” (FG 3, P) | ||||
| Location | 9 | “And I don’t know where colonoscopies are done, but there are people who don’t go to the hospital, so that could be another reason for not doing them.” (FG 2, P5) | ||
| Transportation homea | 8 | “There it goes again. You have to ask someone to pick you up and so on.” (FG 4, P3) | ||
| “Could probably have taken the tram home, but was happy to be taken home by car.” (FG 1, P3) | ||||
| “[…] For insurance reasons, they could not just let me go. And I was not told that before. So that was difficult for me. I then had to call someone, who, fortunately, had time and came. Then there was another discussion about whether I could have gone by public transport, no. […] If I knew before, that this point had been clarified […] But that does not make this colonoscopy itself worse for me.” (FG 3, P5) | ||||
| Follow-up test required | 5 | “Or the doctor then sits in front of you, ‘Yeah, we need to take another look at that.’ That’s dumb. So one person interprets that as, ‘Oh, there might be something there, he just doesn’t have the heart to tell me’, and the other says, ‘Annoying, why didn’t I do the colonoscopy first?’, Yes, if the stool test was done first.” (FG 1, P5) | ||
| Duration | 4 | “When I do a stool test at home, it is done relatively quickly. But such a preparation and then the examination, this small operation already takes time.” (FG 4, P1) | ||
| Mode of test delivery | 1 | “[…] And one would wish for something very safe, comparable to colonoscopy, but—Yes, whether it‘s a test or a very short examination that the general practitioner could also do.” (FG 3, P5) | ||
| Measures of the validity of a screening test | 64 (22) | Predictive valuesa | 32 | “For me, it is important that a procedure provides a really good result. I think, or I do not know, I have not discussed it much now, that a colonoscopy is just much, much safer. And of course it’s more time consuming for me to do it, but I am happy to invest that. So the main criterion for me is to have a really good, safe result.” (FG 1, P2) |
| Sensitivity/Specificity | 21 | “And I think that one is on the safer side with a colonoscopy. You can also see the—you would also catch the precursors.” (FG 4, P) | ||
| 1-Sensitivity/1-Specificity | 11 | “Afterwards, the specialist went into more detail about the stool test, more or less like that—It‘s so sensitive that gum bleeding can be identified, so the probability that the detection of blood in the stool—That this has something to do with some phenomenon in the intestine is not that great.” (FG 3, P2) |
Notes: aInductively derived attributes; bIncludes text passages that indicated a benefit but could not be assigned to a specific benefit outcome due to lack of information; The number after P is the participant’s ID within the respective focus group. Participants within a focus group were numbered from P upwards according to the order in which they first spoke; All anchor samples provided in this table and in the manuscript have been translated from German into English for publication purposes only.
Abbreviations: FG, focus group; P, participant.
Identified Attributes (n, %): Deductively Assigned (n=19; n=217 Codes) and Inductively Derived (n=5; n=76 Codes) Attributes Related to Colorectal Cancer Screening Tests Within and Across All Four Focus Groups
| FG 1 | FG 2 | FG 3 | FG 4 | FG 1 – FG 4 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Deductive | Inductive | Deductive | Inductive | Deductive | Inductive | Deductive | Inductive | Deductive | Inductive | |
| n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |
| Participants | 6 | 6 | 5 | 5 | 5 | 5 | 4 | 4 | 20 | 20 |
| Codes | 57(100) | 20(100) | 59(100) | 18(100) | 68(100) | 23(100) | 33(100) | 15(100) | 217(100) | 76(100) |
| Preparation | 14(25) | 12(20) | 10(15) | 3(9) | 39(18) | |||||
| Procedure | 9(16) | 14(24) | 8(12) | 6(18) | 37(17) | |||||
| Sedationa | 2(10) | 8(44) | 5(22) | 7(47) | 22(29) | |||||
| Purpose | 4(7) | 5(8) | 4(6) | 1(3) | 14(6) | |||||
| Frequency | 1(2) | 1(2) | 9(13) | 0(0) | 11(5) | |||||
| Inability to worka | 2(10) | 1(6) | 5(22) | 3(20) | 11(14) | |||||
| Location | 0(0) | 3(5) | 0(0) | 6(18) | 9(4) | |||||
| Transportation homea | 4(20) | 1(6) | 2(9) | 1(7) | 8(11) | |||||
| Follow-up test required | 1(2) | 0(0) | 4(6) | 0(0) | 5(2) | |||||
| Duration | 3(5) | 0(0) | 0(0) | 1(3) | 4(2) | |||||
| Mode of test delivery | 0(0) | 0(0) | 1(1) | 0(0) | 1(0) | |||||
| Predictive valuesa | 12(60) | 7(39) | 11(48) | 2(13) | 32(42) | |||||
| Sensitivity/Specificity | 7(12) | 3(5) | 6(9) | 5(15) | 21(10) | |||||
| 1-Sensitivity/1-Specificity | 0(0) | 2(3) | 7(10) | 2(6) | 11(5) | |||||
| Reduction in colorectal cancer mortality | 5(9) | 2(3) | 4(6) | 3(9) | 14(6) | |||||
| Reduction in colorectal cancer incidence | 0(0) | 5(8) | 5(7) | 2(6) | 12(6) | |||||
| Colorectal cancer survival | 3(5) | 0(0) | 0(0) | 0(0) | 3(1) | |||||
| Benefitsb | 0(0) | 0(0) | 0(0) | 2(6) | 2(1) | |||||
| Test-related pain and/or discomfort | 3(5) | 8(14) | 3(4) | 2(6) | 16(7) | |||||
| Risk of complications | 0(0) | 2(3) | 6(9) | 0(0) | 8(4) | |||||
| Information processes | 7(12) | 1(2) | 0(0) | 0(0) | 8(4) | |||||
| Waiting time for initial screening colonoscopya | 0(0) | 1(6) | 0(0) | 2(13) | 3(4) | |||||
| Travel time to screening facility | 0(0) | 1(2) | 0(0) | 0(0) | 1(0) | |||||
| Waiting time for follow-up test | 0(0) | 0(0) | 1(1) | 0(0) | 1(0) | |||||
Notes: The bold text indicates the attribute categories; aInductively derived attributes; bIncludes text passages that indicated a benefit but could not be assigned to a specific benefit outcome due to lack of information.
Abbreviation: FG, focus group.